Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-09-15 DOI:10.1080/14622416.2025.2560296

Anmol Kanda, Anjna Rani, Avijit Mazumder

{"title":"Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease.","authors":"Anmol Kanda, Anjna Rani, Avijit Mazumder","doi":"10.1080/14622416.2025.2560296","DOIUrl":null,"url":null,"abstract":"Alzheimer's Disease (AD) represents a formidable challenge in neurology, characterized by progressive neurodegeneration and cognitive decline. Traditional therapeutic approaches have failed to deliver significant outcomes, underscoring the need for innovative paradigms such as precision medicine. The review explores integrating genomic, biomarker-driven, and individualized therapeutic strategies to tackle AD. It examines the role of key genetic factors, including APOE and MTHFR polymorphisms, in influencing disease susceptibility and treatment responses. Advances in biomarker technologies, such as blood-based and imaging biomarkers, are highlighted for their potential in early diagnosis and patient stratification. Additionally, the review underscores the importance of tailoring interventions across different stages of AD, incorporating lifestyle modifications and emerging tools like artificial intelligence & recent patented technologies. Precision medicine offers a transformative pathway, aiming to deliver personalized, effective care that addresses the complex and multifactorial nature of AD. The paradigm shift promises improved clinical outcomes and enhanced patient quality of life.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"1-20"},"PeriodicalIF":1.9000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2025.2560296","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Alzheimer's Disease (AD) represents a formidable challenge in neurology, characterized by progressive neurodegeneration and cognitive decline. Traditional therapeutic approaches have failed to deliver significant outcomes, underscoring the need for innovative paradigms such as precision medicine. The review explores integrating genomic, biomarker-driven, and individualized therapeutic strategies to tackle AD. It examines the role of key genetic factors, including APOE and MTHFR polymorphisms, in influencing disease susceptibility and treatment responses. Advances in biomarker technologies, such as blood-based and imaging biomarkers, are highlighted for their potential in early diagnosis and patient stratification. Additionally, the review underscores the importance of tailoring interventions across different stages of AD, incorporating lifestyle modifications and emerging tools like artificial intelligence & recent patented technologies. Precision medicine offers a transformative pathway, aiming to deliver personalized, effective care that addresses the complex and multifactorial nature of AD. The paradigm shift promises improved clinical outcomes and enhanced patient quality of life.

查看原文本刊更多论文

探索利用个体遗传信息管理阿尔茨海默病的精准医学。

阿尔茨海默病（AD）以进行性神经变性和认知能力下降为特征，是神经学领域的一大挑战。传统的治疗方法未能带来显著的结果，这凸显了对精准医疗等创新范例的需求。这篇综述探讨了整合基因组、生物标志物驱动和个体化治疗策略来治疗AD。它研究了关键遗传因素，包括APOE和MTHFR多态性，在影响疾病易感性和治疗反应中的作用。生物标志物技术的进步，如血液和成像生物标志物，因其在早期诊断和患者分层方面的潜力而受到重视。此外，该综述强调了在AD的不同阶段进行量身定制干预的重要性，包括改变生活方式和人工智能等新兴工具和最新的专利技术。精准医疗提供了一种变革性的途径，旨在提供个性化、有效的护理，解决阿尔茨海默病的复杂性和多因素性质。这种模式的转变有望改善临床结果，提高患者的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.